Narrative Update • Jun 10
Have your own idea? Try our Stock Screener
Australian (ASX) Pharma Industry Analysis
UpdatedJun 21, 2026
DataAggregated Company Financials
Companies29
- 7D-1.6%
- 3M-7.0%
- 1Y-15.4%
- YTD-33.6%
Over the last 7 days, the Pharma industry has dropped 1.6%, driven by a pullback from Neuren Pharmaceuticals of 4.9%. Meanwhile, Avecho Biotechnology actually outperformed within the industry, gaining 36% in the last week. However, the industry is down 15% over the past year. Looking forward, earnings are forecast to grow by 49% annually.
Industry Valuation and Performance
Has the Australian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 21 Jun 2026 | AU$4.1b | AU$875.2m | -AU$363,483,473.00 | 18.8x | -11.3x | 4.7x |
| Tue, 19 May 2026 | AU$4.2b | AU$913.7m | -AU$357,628,473.00 | 13x | -11.6x | 4.5x |
| Thu, 16 Apr 2026 | AU$4.4b | AU$913.7m | -AU$357,628,473.00 | 13.3x | -12.4x | 4.9x |
| Sat, 14 Mar 2026 | AU$4.6b | AU$913.7m | -AU$358,400,628.00 | 13x | -12.7x | 5x |
| Mon, 09 Feb 2026 | AU$4.3b | AU$1.0b | -AU$199,680,775.00 | 10.6x | -21.7x | 4.3x |
| Wed, 07 Jan 2026 | AU$5.7b | AU$1.0b | -AU$199,680,775.00 | 15.3x | -28.8x | 5.7x |
| Fri, 05 Dec 2025 | AU$5.3b | AU$1.0b | -AU$199,680,775.00 | 14.1x | -26.7x | 5.3x |
| Sun, 02 Nov 2025 | AU$6.5b | AU$1.0b | -AU$202,211,775.00 | 14.1x | -32x | 6.5x |
| Tue, 30 Sep 2025 | AU$5.7b | AU$1.0b | -AU$202,211,775.00 | 14.6x | -28.4x | 5.7x |
| Thu, 28 Aug 2025 | AU$5.5b | AU$1.0b | -AU$177,081,317.00 | 14.2x | -30.8x | 5.3x |
| Sat, 26 Jul 2025 | AU$5.3b | AU$1.1b | -AU$225,511,927.00 | 14.6x | -23.3x | 5x |
| Mon, 23 Jun 2025 | AU$4.2b | AU$1.1b | -AU$225,511,927.00 | 13.9x | -18.6x | 4x |
| Wed, 21 May 2025 | AU$4.6b | AU$1.0b | -AU$238,266,485.00 | 17.4x | -19.4x | 4.4x |
| Fri, 18 Apr 2025 | AU$4.2b | AU$1.0b | -AU$238,266,485.00 | 17.5x | -17.4x | 4x |
| Sun, 16 Mar 2025 | AU$4.7b | AU$1.1b | -AU$289,508,485.00 | 18.5x | -16.4x | 4.5x |
| Tue, 11 Feb 2025 | AU$5.5b | AU$1.0b | -AU$377,224,948.00 | 13.1x | -14.5x | 5.4x |
| Thu, 09 Jan 2025 | AU$5.3b | AU$1.0b | -AU$378,981,112.00 | 12.5x | -14.1x | 5.3x |
| Sat, 07 Dec 2024 | AU$5.8b | AU$1.0b | -AU$378,981,112.00 | 13.1x | -15.2x | 5.7x |
| Mon, 04 Nov 2024 | AU$6.0b | AU$1.0b | -AU$377,703,112.00 | 13x | -15.9x | 5.9x |
| Wed, 02 Oct 2024 | AU$7.1b | AU$1.0b | -AU$370,332,028.00 | 12.9x | -19.1x | 7x |
| Fri, 30 Aug 2024 | AU$6.4b | AU$1.0b | -AU$315,863,798.00 | 12.8x | -20.4x | 6.2x |
| Sun, 28 Jul 2024 | AU$6.7b | AU$995.3m | -AU$387,920,108.00 | 11.6x | -17.4x | 6.8x |
| Tue, 25 Jun 2024 | AU$6.1b | AU$995.3m | -AU$387,920,108.00 | 11.6x | -15.8x | 6.1x |
| Thu, 23 May 2024 | AU$6.1b | AU$1.2b | -AU$374,923,684.00 | 13.8x | -16.3x | 5x |
| Sat, 20 Apr 2024 | AU$5.6b | AU$1.2b | -AU$374,923,684.00 | 14.8x | -15x | 4.6x |
| Mon, 18 Mar 2024 | AU$5.5b | AU$1.2b | -AU$374,923,684.00 | 14.6x | -14.8x | 4.6x |
| Wed, 14 Feb 2024 | AU$5.7b | AU$892.7m | -AU$536,464,511.00 | 20.7x | -10.6x | 6.4x |
| Fri, 12 Jan 2024 | AU$5.7b | AU$896.3m | -AU$589,604,392.00 | 21.2x | -9.6x | 6.3x |
| Sun, 10 Dec 2023 | AU$4.3b | AU$896.3m | -AU$589,604,392.00 | 16.7x | -7.4x | 4.8x |
| Tue, 07 Nov 2023 | AU$3.8b | AU$893.0m | -AU$595,020,018.00 | 18.4x | -6.4x | 4.2x |
| Thu, 05 Oct 2023 | AU$3.5b | AU$900.3m | -AU$587,952,018.00 | 19x | -6x | 3.9x |
| Sat, 02 Sep 2023 | AU$3.9b | AU$929.9m | -AU$616,143,380.00 | 19.8x | -6.3x | 4.2x |
| Mon, 31 Jul 2023 | AU$4.2b | AU$999.0m | -AU$624,794,303.00 | 22.4x | -6.8x | 4.2x |
| Wed, 28 Jun 2023 | AU$3.9b | AU$999.0m | -AU$624,794,303.00 | 20.7x | -6.2x | 3.9x |
Price to Earnings Ratio
-6.2x
Current Industry PE
- Investors are relatively neutral on the Australian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 4.3% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.56% | |
| Healthcare | 5.64% | |
| Pharma | -1.60% | |
| Pharma | -1.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AVE Avecho Biotechnology | AU$0.015 | 36.4% +AU$15.3m | 275.0% | PS46.4x | |
| LTP LTR Pharma | AU$0.59 | 9.3% +AU$9.1m | 100.0% | PS94.8x | |
| CU6 Clarity Pharmaceuticals | AU$2.17 | 0.9% +AU$7.4m | 4.3% | PS76.4x | |
| SPL Starpharma Holdings | AU$0.69 | 2.2% +AU$6.3m | 689.8% | PS20.1x | |
| NYR Nyrada | AU$0.47 | 5.7% +AU$6.1m | 89.8% | PS47.9x |
